x

Posted 03 October, 2022

Imunon, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:IMNN in a 8-K filed on 03 October, 2022.


  On October 3, 2022, Imunon, Inc. (the "Company") announced that the Board of Directors (the "Board") appointed James E. Dentzer to the Board as a Class II Director effective September 29, 2022. Mr. Dentzer has served as the President and Chief Executive Officer and a member of the Board of Directors of Curis, Inc. ("Curis"), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, since September 2018.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Imunon, Inc.
Health Care/Life Sciences • Biotechnology
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Market Cap
$12.9M
View Company Details
Imunon, Inc. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers


On October 3, 2022, Imunon, Inc. (the "Company") announced that the Board of Directors (the "Board") appointed James E. Dentzer to the Board as a Class II Director effective September 29, 2022. Mr. Dentzer has served as the President and Chief Executive Officer and a member of the Board of Directors of Curis, Inc. ("Curis"), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, since September 2018. From March 2018 to September 2018, Mr. Dentzer served as Curis' Chief Operating Officer and Chief Financial Officer. From March 2016 to March 2018, Mr. Dentzer served as Curis' Chief Administrative Officer and Chief Financial Officer. Mr. Dentzer also held the positions of secretary and treasurer at Curis from March 2016 to March 2019. Prior to joining Curis, Mr. Dentzer served as Chief Financial Officer of Dicerna Pharmaceuticals, Inc., a biotechnology company, from December 2013 to December 2015. Prior to such role, he was the Chief Financial Officer of Valeritas, Inc., a medical technology company, from March 2010 to December 2013. Before joining Valeritas, Inc., he was the Chief Financial Officer of Amicus Therapeutics, Inc., a biotechnology company, from October 2006 to October 2009. In prior positions, he spent six years as Corporate Controller of Biogen Inc., a biotechnology company, and six years in various senior financial roles at E.I. du Pont de Nemours and Company, a chemical, petroleum and biotechnology company, in the U.S. and Asia. Mr. Dentzer holds a B.A. in philosophy from Boston College and an M.B.A. from the University of Chicago.


Mr. Dentzer's Class II term will expire at the Company's Annual Meeting of Stockholders in 2024. Mr. Dentzer will receive standard non-employee director fees, including an initial grant of stock options under the Company's 2018 Stock Incentive Plan, as amended (the "Plan"), to purchase 2,667 shares of the Company's common stock, vesting in three equal installments with the first vesting date on January 1, 2023, and annually thereafter.


The Board has determined that Mr. Dentzer is an independent director in accordance with the applicable rules of the SEC and The NASDAQ Stock Market. Mr. Dentzer does not have any relationship with the Company that would require disclosure pursuant to Item 404(a) of SEC Regulation S-K.


On October 3, 2022, the Company issued a press release announcing the appointment of Mr. Dentzer, a copy of which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.